Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00789776
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:26.030170+00:00
Published At
2018-07-12T00:00:00+00:00
Record Updated At
2020-01-31
Results Posted At
2018-07-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Aggressive Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Previously Treated Myelodysplastic Syndrome", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Small Lymphocytic Lymphoma", "Waldenstrom Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-01-31"
protocolSection.identificationModule.nctId
"NCT00789776"
protocolSection.identificationModule.officialTitle
"A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-07-12"

Study condition terms

  • Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Aggressive Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Indolent Adult Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Refractory Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.